Sexually transmitted infections · 2000
The sac-4 gene of Neisseria gonorrhoeae and co-existing chlamydial infection.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Phillips D J, Patrizio C, Moyes A, Young H
Аннотация
BACKGROUND/OBJECTIVES: Recently, the sac-4 gene in Neisseria gonorrhoeae was postulated to increase the risk of developing mixed gonococcal and chlamydial infection. The aims of this study were to determine the frequency of the sac-4 gene in a larger sample of isolates of different serovars and to assess the prevalence of sac-4 in gonococcal isolates from patients with and without coexisting chlamydial infection.
METHODS: Isolates from 259 episodes of gonorrhoea were tested by a PCR assay for the sac-4 gene. The presence of co-existing chlamydial infection was determined from both laboratory and GUM clinical records.
RESULTS: The overall prevalence of sac-4 was 57.5% (149/259). The prevalence was not the same in all serovars and ranged from 34.9% in serovar 1B2 to 100% in serovar 1B18. Exact logistic regression analysis indicated significant differences in sac-4 prevalence in isolates of different serovars. The prevalence of sac-4 was 69.5% (41/59) in gonococcal isolates from patients with co-existing chlamydial infection compared with 57.9% (62/107) for those without chlamydial infection. Exact logistic regression analysis showed that the slightly increased sac-4 prevalence among chlamydia positive patients (p = 0.2) virtually disappeared when serovar status was taken into account (p > 0.9).
CONCLUSION: The sac-4 gene of the gonococcus does not increase the risk for mixed chlamydial infection.
METHODS: Isolates from 259 episodes of gonorrhoea were tested by a PCR assay for the sac-4 gene. The presence of co-existing chlamydial infection was determined from both laboratory and GUM clinical records.
RESULTS: The overall prevalence of sac-4 was 57.5% (149/259). The prevalence was not the same in all serovars and ranged from 34.9% in serovar 1B2 to 100% in serovar 1B18. Exact logistic regression analysis indicated significant differences in sac-4 prevalence in isolates of different serovars. The prevalence of sac-4 was 69.5% (41/59) in gonococcal isolates from patients with co-existing chlamydial infection compared with 57.9% (62/107) for those without chlamydial infection. Exact logistic regression analysis showed that the slightly increased sac-4 prevalence among chlamydia positive patients (p = 0.2) virtually disappeared when serovar status was taken into account (p > 0.9).
CONCLUSION: The sac-4 gene of the gonococcus does not increase the risk for mixed chlamydial infection.